GlassScriptPhysician profile
Kazi S Rahman
NPI 1801222732
$4,228.91
in general payments reported to CMS, 2019-2025
25 companies · $741 in 2025
The $741 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,498 · 2020: $1,000 · 2021: $277 · 2022: $165 · 2023: $134 · 2024: $414 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $966.75 | 2024-2025 | |
| Arthrex, INC. | $910.12 | 2020 | |
| Wright Medical Technology, INC. | $635.71 | 2019 | |
| Smith+Nephew, INC. | $367.28 | 2019-2025 | Grafix Pl |
| Organogenesis INC. | $308.14 | 2019-2023 | Puraply |
| Djo, LLC | $303.50 | 2019 | |
| Skeletal Dynamics INC | $175.00 | 2019 | |
| Nevro Corp. | $114.07 | 2023-2024 | Senza |
| Pacira Therapeutics, INC. | $96.53 | 2019-2021 | |
| Bioventus LLC | $50.77 | 2019-2021 | |
| Cornerstone Medical Associates, INC. | $49.30 | 2025 | |
| Pfizer INC. | $38.14 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $32.34 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $22.74 | 2023 | |
| Vanda Pharmaceuticals INC. | $19.18 | 2024 | Hetlioz, Fanapt |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.54 | 2022 | |
| Heron Therapeutics, INC. | $15.91 | 2021 | |
| Si-Bone, INC. | $15.73 | 2021 | |
| Kci USA, INC. | $15.73 | 2019 | |
| Melinta Therapeutics, LLC | $15.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.75 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.36 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.13 | 2022 | |
| Merck Sharp & Dohme LLC | $11.41 | 2019 | |
| Acell, INC. | $10.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kazi Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.